The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma.
 
Mark R. Middleton
Honoraria - Amgen; Roche
Consulting or Advisory Role - BiolineRx; Bristol-Myers Squibb; CytomX Therapeutics; Immunocore; Johnson & Johnson; Merck; Newlink Genetics; Novartis; RigonTEC
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); RigonTEC (Inst); Roche (Inst); TC Biopharm (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck
 
Neil Matthew Steven
Consulting or Advisory Role - Incyte
Travel, Accommodations, Expenses - Incyte
 
TR Jeffry Evans
Honoraria - Bristol-Myers Squibb; Eisai
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Eisai; Karus Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Eisai
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Lilly (Inst); Merck (Inst); Nutide (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Sierra Pharma (Inst); Verastem (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Intensity Therapeutics; Torque
Consulting or Advisory Role - Abbvie; Adaptimmune; Allakos; Almac Diagnostics; Array BioPharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Celldex; Genentech/Roche; Genmab; Gritstone Bio; Hinge Bio; immunocore; Incyte; Innate Pharma; Inovio Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck Sharp & Dohme; Modulate Pharma; Molecular Partners; Nektar; Newlink Genetics; Novartis; Omniox; Pieris Pharmaceuticals; Pierre Fabre; Seagen; Symphogen; Theravance; Torque
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico
 
Omid Hamid
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Novartis; Sanofi/Regeneron
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); NextCure (Inst); Novartis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pfizer (Inst); Polynoma (Inst); Regeneron (Inst); Roche (Inst)
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Immunocore; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Alan Anthoney
Consulting or Advisory Role - Advanced Accelerator Applications; Ono Pharmaceutical
Research Funding - Immunocore (Inst)
 
Avinash Gupta
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Victoria K Woodcock
Travel, Accommodations, Expenses - MSD
 
Rachael Easton
Employment - Immunocore; Janssen Oncology (I); Sanofi
Stock and Other Ownership Interests - Johnson & Johnson (I); Sanofi
 
Philippa Gail Corrie
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Halozyme (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme